TXMD: TherapeuticsMD, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 25.77
Enterprise Value ($M) 15.60
Book Value ($M) 28.05
Book Value / Share 2.45
Price / Book 0.92
NCAV ($M) -5.00
NCAV / Share -0.44
Price / NCAV -5.15

Profitability (mra)
Return on Invested Capital (ROIC) 1.88
Return on Assets (ROA) 0.76
Return on Equity (ROE) 1.94

Liquidity (mrq)
Quick Ratio 1.20
Current Ratio 1.20

Balance Sheet (mrq) ($M)
Current Assets 17.44
Assets 50.49
Liabilities 22.44
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-17 13D/A Rubric Capital Management LP 25.73 42.38

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION R
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPOR
2023-05-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION R
2023-04-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-03-27 2,646 12,312 21.49
2024-03-26 2,971 9,292 31.97
2024-03-25 2,349 14,177 16.57
2024-03-22 9,407 36,752 25.60

(click for more detail)

Similar Companies
TSHA – Taysha Gene Therapies, Inc. TSVT – 2seventy bio, Inc.
TWST – Twist Bioscience Corporation TYRA – Tyra Biosciences, Inc.
UBX – Unity Biotechnology, Inc.


Financial data and stock pages provided by
Fintel.io


Finpedia: TherapeuticsMD